Relmada Therapeutics, Inc.
RLMD · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.02 | 0.02 | -0.01 |
| FCF Yield | -32.13% | -220.05% | -56.08% | -68.15% |
| EV / EBITDA | -1.82 | -0.39 | -0.63 | -1.00 |
| Quality | ||||
| ROIC | -63.96% | -81.16% | -53.70% | -48.30% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.67 | 0.65 | 1.03 | 0.47 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 64.57% | -105.32% | 47.17% | -25.59% |
| Safety | ||||
| Net Debt / EBITDA | 0.13 | 0.06 | 0.21 | 0.06 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |